Skip to main content

Dementia modelling


Start Date
End Date
Total Funding
€ 853 452
Funding Programme
European Countries Involved

Dementia constitutes a major burden on society, both in monetary costs and the suffering of patients and their relatives. It comprises a number of diseases including Alzheimer’s disease (AD) and vascular dementia (VaD). In recent years, imaging biomarkers have been developed including measures of brain morphology (MRI T1), vascular pathologies (MRI T2*/FLAIR), white matter abnormalities (MRI DWI), perfusion (MRI ASL), glucose turnover (PET FDG), and accumulation of pathological proteins (PET PIB/AV45). Quantitative measures using these biomarkers in large cohort studies have the potential to model the pathological process of the disease. This proposal would create an innovative training network, in which early stage researchers will develop new computational imaging biomarkers, under the supervision of experienced researchers, for the purpose of modeling dementia etiology. One researcher will investigate quantification of vascular pathologies, another will develop quantitative measures of white matter abnormalities from structural MRI, and the final researcher will construct a quantitative model of disease etiology using a maximum-likelihood framework. The early stage researchers will be enrolled as PhD students at University College London (UCL) under the EPSRC Centre for Doctoral Training in Medical Imaging (CDT), which is based in Centre for Medical Image Computing (CMIC), with the Dementia Research Centre (DRC) being one of the main clinical collaborators for CDT studentships. However, they will spend the majority of time at the research facilities of Biomediq A/S, Copenhagen Denmark, where they will be exposed to industry and work under professional guidance.

Project partners

University College London
King'S College London
Biomediq As

Alzheimer Europe's database on research projects was developed as part of the 2020 Work Plan which received funding under an operating grant from the European Union’s Health Programme (2014–2020).